Epigral Limited has disclosed its audited consolidated and standalone financial results for the fourth quarter and full year ended March 31, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 2, 2026. Newspaper advertisements were published on May 3, 2026 and May 4, 2026 in the Financial Express (English and Gujarati editions) and Jai Hind (Gujarati edition).

Consolidated Financial Performance

Epigral's consolidated financial results reflect the company's performance across the fourth quarter and the full financial year ended March 31, 2026. The following table presents the key consolidated financial metrics (₹ In Crore, except as stated otherwise):

Standalone Financial Performance

The standalone financial results for the quarter and year ended March 31, 2026 are summarised below (₹ In Crore, except as stated otherwise):

Regulatory Compliance and Publication Details

The financial results have been prepared in compliance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs. The results represent an extract of the detailed format filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the websites of the stock exchanges as well as on the company's website at www.epigral.com . The results were signed by Maulin Patel, Chairman and Managing Director (DIN 02006947), on behalf of the Board of Directors, from Ahmedabad, dated May 2, 2026.

Epigral Limited has filed its audited financial results for Q4FY26 with the National Stock Exchange and BSE Limited under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company reported highest ever quarterly revenue of ₹736.16 crore and recommended a final dividend of ₹5 per share, representing 50% of face value of ₹10. The Board meeting was held on May 2, 2026, at the registered office in Ahmedabad.

Conference Call Recording Available

Following the Q4FY26 results announcement, Epigral Limited has made available the audio recording of the conference call discussing the quarterly results. The conference call was held on Saturday, May 2, 2026 at 4:30 p.m. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, the company has provided access to the audio recording through its official website. The recording is available at the company's results section and provides detailed discussions on the Q4FY26 performance.

Operational Performance Highlights

The company demonstrated strong operational metrics with 15% sequential sales volume growth and plant utilization exceeding 80% in Q4FY26. This operational efficiency contributed significantly to the revenue recovery and improved financial performance during the quarter. The Derivatives & Specialty business contributed 54% of revenue in Q4FY26 compared to 52% in Q3FY26.

Q4FY26 Financial Performance

The fourth quarter demonstrated exceptional performance with revenue reaching ₹736.16 crore, marking a 17% YoY growth from ₹627.63 crore in Q4FY25. On sequential basis, the company witnessed strong recovery with 22% QoQ growth from ₹597.12 crore in Q3FY26. PAT stood at ₹81.93 crore for the quarter, showing 109% QoQ improvement from ₹39.15 crore in Q3FY26. EBITDA for the quarter was ₹169 crore with a margin of 23%.

FY2026 Annual Performance and Capex Plans

For the full year, revenue stood at ₹2,542.16 crore, a 1% decline from ₹2,565.34 crore in FY2025 due to a 4% drop in sales volume. PAT for FY26 was ₹333.01 crore compared to ₹356.70 crore in FY25. The company spent ₹394.15 crore on capital expenditure in FY2026, with expansion projects progressing as per schedule. CPVC Resin capacity will reach 1,50,000 TPA by adding 75,000 TPA, while Epichlorohydrin capacity will reach 1,00,000 TPA by adding 50,000 TPA, both expected to be commissioned in H1FY27.

Management Commentary and Strategic Outlook

Maulik Patel, Chairman and Managing Director, highlighted the strong operational performance driven by 15% sequential volume growth and improved plant utilization above 80%. Patel noted that demand recovery began in November and strengthened through Q4, with momentum expected to continue into FY27 subject to global macro conditions. The company has also invested in renewable energy through agreements with Pro-Zeal Green Power Ten Private Limited for a 19.80 MW Wind Solar Hybrid Power Plant in Gujarat.

Regulatory Filing and Recognition

The audited financial results were approved by the Board on May 2, 2026, and filed by Company Secretary & Compliance Officer Gaurang Trivedi. The statutory auditors M/s. S R B C & CO LLP issued audit reports with unmodified opinion. Epigral has been awarded the EcoVadis Silver Medal and its Responsible Care certification has been renewed for another three years. The company is expanding its Wind Solar Hybrid Power Plant capacity to 38.14 MW by adding 19.80 MW, demonstrating commitment to sustainable operations.